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12 Abstract This study aimed to elucidate the genetic related-
13 ness and epidemiology of 127 clinical and environmental
14 Candida glabrata isolates from Europe and Africa using
15 multilocus microsatellite analysis. Each isolate was first iden-
16 tified using phenotypic and molecular methods and subse-
17 quently, six unlinked microsatellite loci were analyzed using
18 automated fluorescent genotyping. Genetic relationships were
19 estimated using the minimum-spanning tree (MStree) method.
20 Microsatellite analyses revealed the existence of 47 different
21 genotypes. The fungal population showed an irregular distri-
22 bution owing to the over-representation of genetically differ-
23 ent infectious haplotypes. The most common genotype was
24 MG-9, which was frequently found in both European and
25 African isolates. In conclusion, the data reported here empha-
26 size the role of specific C. glabrata genotypes in human in-
27 fections for at least some decades and highlight the wide-
28 spread distribution of some isolates, which seem to be more
29 able to cause disease than others.30
31Introduction
32Candida glabrata is a haploid yeast historically believed to be
33harmless to humans and for a long time regarded as a non-
34pathogenic saprophyte of the normal flora of healthy individ-
35uals [1]. However, in recent decades, this view has been grad-
36ually weakened as a growing number of clinical reports have
37shown that this fungus is, on the contrary, an important path-
38ogen [2–4].
39The increase in patients with an impaired immune system,
40in addition to the widespread use of immunosuppressive ther-
41apies and broad-spectrum antibiotic drugs, has greatly contrib-
42uted to rendering C. glabrata one of the most commonly iso-
43lated yeasts among all non-C. albicans species that infect
44humans [2–4]. However, although Candida albicans remains
45the most frequently isolated fungal pathogen in humans,
46C. glabrata has been reported to be an significant cause of
47oral infections, especially in elderly people [4, 5]. In addition,
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48 this species also shows a remarkable ability to infect other
49 human body sites including the vagina and urinary tract [6,
50 7], and in recent years it has undoubtedly emerged as the
51 second-leading cause of bloodstream infections (BSIs) in the
52 USA and in Northern and Central European countries [3].
53 The reasons for the increased isolation rate of C. glabrata
54 are multifactorial and difficult to pinpoint exactly. However,
55 the issue of resistance to azole derivatives [3, 8] and the dis-
56 covery and evolution of new strains [9, 10] are certainly partly
57 responsible.
58 For population genetics studies in C. glabrata,
59 microsatellites have increasingly become the markers of choice
60 [11–14]. Most microsatellites are noncoding DNA, either in
61 intergenic sequence regions or in introns. Thus, they can gen-
62 erally be assumed to evolve neutrally; thus, their level of poly-
63 morphism is proportional to the underlying mutation rate.
64 In this study, we report the genetic profiles, obtained
65 through analysis of six microsatellite loci, of different clinical
66 and environmental C. glabrata isolates from Europe and
67 Africa. Our data showed a south–north and east–west distri-
68 bution of closely related genotypes and highlight the wide-
69 spread distribution of particular haplotypes, which seem to
70 be more able to cause infections than others.
71 Materials and methods
72 A total of 127 C. glabrata isolates, of different clinical and
73 geographical origin, were examined in this study (Table 1).
74 All isolates were initially identified by the ID 32C system
75 (bioMeriéux, France) and subsequently confirmed using a
76 species-specific multiplex PCR-based method that allows
77 C. glabrata to be discriminated from its closely related species
78 Candida bracarensis and Candida nivariensis [15, 16].
79 Multilocus analysis of polymorphic microsatellite markers
80 was used to evaluate genetic relatedness among our
81 C. glabrata isolates [11]. Six microsatellite markers were ampli-
82 fied by PCR using six pairs of primers, as described in Abbes
83 et al. [11]. For automatic allele size determination the forward
84 primer of each pair was 5′-fluorescently labelled with 6-
85 carboxyfluorescein (FAM; GLM4-Fwd, GLM6-Fwd, RPM2-
86 Fwd and MTI-Fwd primers), 6-carboxyhexafluorescein (HEX;
87 GLM5-Fwd primer), and 6-carboxytetramethylrhodamine
88 (TAMRA; ERG3-Fwd primer). For each isolate, six separate
89 PCR amplifications were performed and amplicons were sent
90 out to Eurofins-MWG/Operon (www.eurofinsdna.com) for
91 fragment length analysis using an ABI 3130XL sequencing
92 platform (Applied Biosystems) and GeneScan 500-ROX as the
93 size standard. Allele binning was carried out using the program
94 AutoBin [17]. Genetic relationships were estimated using the
95 minimum-spanning tree (MStree) method, as implemented in
96 BioNumerics, version 4.61 (Applied Maths, St.-Martens-
97 Latem, Belgium).
98The discriminatory power (D) of the microsatellite typing
99method used was calculated on-line (http://insilico.ehu.es/
100mini_tools/discriminatory_power/index.php) using
101Simpson’s index of diversity [18].
102For statistical analysis, all isolates were split according to
103their geographical origin: Africa (n = 22), Greece (n = 15),
104Italy (n = 30), Portugal (n = 15), Spain (n = 16), Turkey
105(n = 16) and Middle/Northern Europe (UK, the Netherlands,
106Austria, Finland, and Germany; n = 13). Haplotype frequen-
107cies and genetic diversity within each population in addition to
108inter-population analysis were computed using the software
109HAPLOTYPE ANALYSIS version 1.05 (www.uni-
110goettingen.de/en/134935.html). HAPLOTYPE ANALYSIS
111calculates genetic diversity within each population based on
112the number of different haplotypes (A) in that population, the
113number of unique or “private” haplotypes (P) specific to that
114population, the effective number of haplotypes (Ne) observed
115in the population, the estimated maximum haplotype richness
116or “allele richness” (Rh) defined as the number of alleles per
117locus and based on the rarefaction method, Nei’s index of
118genetic diversity (He; the probability that two randomly cho-
119sen haplotypes are different) estimated without bias and the
120mean genetic distance between individuals (Dsh
2) as measures
121for genetic diversity.
122Fisher’s exact tests were used to test whether there were
123statistical differences in the proportion of the genotypes
124among the different countries. To better quantify the differ-
125ence between the countries, we used the four clonal com-
126plexes (CCs) recognized in the 47 different microsatellite ge-
127notypes by theMStree in Fig. 1. These CCs were grouped into
128four classes based around the central genotypes.The classified
129C. glabrata populations were compared using Fisher’s exact
130test giving us the probability that populations were similar
131(p values >0.05) or dissimilar (p values <0.05).
132Results
133All yeast isolates examined in this study were identified as
134C. glabrata isolates and no C. nivariensis or C. bracarensis
135were recovered. The multilocus microsatellite genotypes ob-
136tained are shown in Table 1 and Fig. 1.
137A total of 84 different alleles were found for the six micro-
138satellite loci analyzed (Table 2). Locus ERG3 showed the
139highest genotypic diversity with a D value of 0.85, whereas
140the lowest genotypic diversity was observed with the locus
141GLM5 (D=0.62; Table 2).
142When all six microsatellite markers were combined, a total
143of 47 diverse multilocus genotypes (MG) were obtained from
144127 C. glabrata isolates (Fig. 1, Table 1). This led to an index
145of discrimination of 0.89 (Table 2).
146One genotype (MG-9) was the most frequently observed
147(37 out of 127 isolates; 29 %) followed by genotypes MG-34
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t1:1 Table 1 Results obtained by microsatellite genotyping analysis of the European and African C. glabrata isolates examined in this study
t1:2 Isolate Origin Year Samples Microsatellite loci Genotype
t1:3 ERG3 RPM2 MTI GLM4 GLM5 GLM6
t1:4 CG125 Italy 2006 BPS 230 139 239 279 262 300 MG-1
t1:5 CG2018 Italy 2007 Sputum 200 125 233 284 258 295 MG-17
t1:6 CGES1 Italy 2012 Sputum 264 127 239 277 258 324 MG-4
t1:7 CGES2 Italy 2012 Sputum 207 133 239 265 258 324 MG-9
t1:8 CG2051 Italy 2007 BAL 201 127 238 275 298 295 MG-20
t1:9 CG3416 Italy 2008 BAL 207 133 239 265 258 324 MG-9
t1:10 CG4157 Italy 2009 BAL 207 133 239 265 258 324 MG-9
t1:11 CG3285La Italy 2008 BAL 230 139 239 279 262 300 MG-1
t1:12 CG3285Sa Italy 2008 Blood 230 139 239 279 262 300 MG-1
t1:13 CG3399 Italy 2008 Blood 207 133 239 265 258 324 MG-9
t1:14 CG157 Italy 2006 CVC 207 133 239 265 258 324 MG-9
t1:15 CG4795 Italy 2009 CVC 264 127 239 280 258 324 MG-5
t1:16 CG4768 Italy 2009 CVC 264 127 239 280 258 324 MG-5
t1:17 CG1626 Italy 2007 Feces 264 127 239 280 258 324 MG-5
t1:18 CG1724 Italy 2007 Feces 230 139 239 279 262 300 MG-1
t1:19 CG1828 Italy 2007 Feces 194 121 248 268 262 295 MG-25
t1:20 CG2081 Italy 2007 Feces 264 127 239 277 258 324 MG-4
t1:21 CG2086 Italy 2007 Feces 207 133 239 265 258 324 MG-9
t1:22 CG4836 Italy 2009 Feces 264 127 239 277 258 324 MG-4
t1:23 CG1580 Italy 2007 Urine 207 133 239 265 258 324 MG-9
t1:24 CG2108 Italy 2007 Urine 237 121 239 265 258 287 MG-12
t1:25 CG2453 Italy 2008 Urine 201 127 238 275 298 295 MG-20
t1:26 CG4819 Italy 2009 Urine 207 133 239 265 258 324 MG-9
t1:27 CGLA1 Italy 2011 Urine 207 133 239 265 258 324 MG-9
t1:28 CG1721 Italy 2010 Vaginal 230 127 239 268 258 324 MG-7
t1:29 CG1818 Italy 2007 Vaginal 207 133 239 265 258 324 MG-9
t1:30 CG2074 Italy 2007 Vaginal 276 127 233 280 264 310 MG-22
t1:31 CG2087 Italy 2007 Vaginal 237 133 248 280 270 305 MG-24
t1:32 CG4165 Italy 2009 Vaginal 207 133 239 265 258 324 MG-9
t1:33 CG4206 Italy 2012 Vaginal 207 133 239 265 258 324 MG-9
t1:34 NIG10 Nigeria 2011 Vaginal 264 127 239 277 258 324 MG-4
t1:35 NIG16p Nigeria 2011 Vaginal 264 127 239 277 258 324 MG-4
t1:36 NIG19Bp Nigeria 2011 Vaginal 237 133 238 268 258 295 MG-13
t1:37 NIG29p Nigeria 2011 Vaginal 207 133 239 265 258 324 MG-9
t1:38 NIG64 Nigeria 2011 Vaginal 207 133 239 265 258 324 MG-9
t1:39 NIG71 Nigeria 2011 Vaginal 207 133 239 265 258 324 MG-9
t1:40 NIG108p Nigeria 2011 Vaginal 207 133 239 265 258 324 MG-9
t1:41 NIG154 Nigeria 2011 Vaginal 207 133 239 265 258 324 MG-9
t1:42 NIG157p Nigeria 2011 Vaginal 207 133 239 265 258 324 MG-9
t1:43 NIG162p Nigeria 2011 Vaginal 264 127 246 277 258 324 MG-6
t1:44 NIG173p Nigeria 2011 Vaginal 207 133 239 265 258 324 MG-9
t1:45 NIG176 Nigeria 2011 Vaginal 241 145 238 268 262 321 MG-32
t1:46 NIG190p Nigeria 2011 Vaginal 264 127 239 277 258 324 MG-4
t1:47 NIG194 Nigeria 2011 Vaginal 237 133 238 268 258 295 MG-13
t1:48 NIG222p Nigeria 2011 Vaginal 264 127 239 277 258 324 MG-4
t1:49 NIG223p Nigeria 2011 Vaginal 237 133 238 280 258 295 MG-14
t1:50 NIG244 Nigeria 2011 Vaginal 207 133 239 265 258 324 MG-9
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t1:51 Table 1 (continued)
Isolate Origin Year Samples Microsatellite loci Genotype
t1:52 ERG3 RPM2 MTI GLM4 GLM5 GLM6
t1:53 CBS12544 Zimbabwe 2011 Fruit pulp 237 127 232 268 258 289 MG-16
t1:54 CBS2175 UK 1955 Vaginal 207 133 239 268 258 324 MG-10
t1:55 CBS2192 South Africa 1955 Malt 207 133 239 265 258 324 MG-9
t1:56 CBS2498 Netherlands 1956 Medium ph2 264 127 239 277 258 324 MG-4
t1:57 CBS4692 Austria – GM 207 133 239 265 258 324 MG-9
t1:58 CBS5040 South Africa – Insect larvae 207 133 239 265 258 324 MG-9
t1:59 CBS6144 Finland – Vaginal 230 127 239 268 258 324 MG-7
t1:60 CBS860 Netherlands 1935 Urine 207 133 239 265 258 324 MG-9
t1:61 CBS861 Netherlands 1942 Mouth 207 133 239 280 258 324 MG-11
t1:62 CBS862 Netherlands 1948 Mouth 230 127 239 268 258 324 MG-7
t1:63 CGS-65 Spain 2011 Blood 207 133 239 265 258 324 MG-9
t1:64 CGS-66 Spain 2011 Blood 207 133 239 265 258 324 MG-9
t1:65 CGS-67 Spain 2011 Blood 207 133 239 265 258 324 MG-9
t1:66 CGS-68 Spain 2011 Blood 264 127 239 277 258 324 MG-4
t1:67 CGS-75 Spain 2012 Blood 207 133 239 265 258 324 MG-9
t1:68 CGS-77 Spain 2013 Blood 230 127 239 268 258 324 MG-7
t1:69 CGS-78 Spain 2013 Blood 230 127 239 268 258 324 MG-7
t1:70 CGS-79 Spain 2013 Blood 207 133 239 265 258 324 MG-9
t1:71 CGS-80 Spain 2013 Blood 207 133 239 265 258 324 MG-9
t1:72 CGS-81 Spain 2013 Blood 216 122 242 268 264 307 MG-29
t1:73 CGS-82 Spain 2013 Blood 194 121 247 268 260 295 MG-26
t1:74 CGS-86 Spain 2014 Blood 207 133 239 265 258 324 MG-9
t1:75 CGS-87 Spain 2014 Blood 230 127 239 268 258 324 MG-7
t1:76 CGS-88 Spain 2014 Blood 276 127 232 280 264 310 MG-23
t1:77 CGS-89 Spain 2014 Blood 215 127 225 268 282 321 MG-44
t1:78 CGS-90 Spain 2014 Blood 202 121 225 277 273 307 MG-30
t1:79 GER1 Germany 2015 Vaginal 230 139 239 277 260 298 MG-2
t1:80 GER2 Germany 2015 Vaginal 230 139 239 268 258 280 MG-3
t1:81 GER3 Germany 2015 Vaginal 216 133 238 271 258 324 MG-15
t1:82 GER4 Germany 2015 Vaginal 230 127 239 265 258 324 MG-8
t1:83 GER5 Germany 2015 Vaginal 207 133 239 265 258 324 MG-9
t1:84 GER6 Germany 2015 Vaginal 207 133 239 265 258 324 MG-9
t1:85 GRE1 Greece 2010 Vaginal 237 127 232 268 258 289 MG-16
t1:86 GRE2 Greece 2010 Vaginal 230 139 239 277 260 298 MG-2
t1:87 GRE3 Greece 2010 Vaginal 201 125 238 268 270 290 MG-21
t1:88 GRE5 Greece 2010 Vaginal 194 121 247 268 260 283 MG-27
t1:89 GRE6 Greece 2010 Vaginal 194 127 247 268 260 310 MG-28
t1:90 GRE8 Greece 2010 Vaginal 230 139 239 277 260 298 MG-2
t1:91 GRE9 Greece 2010 Vaginal 207 133 239 265 258 324 MG-9
t1:92 GRE10 Greece 2010 Vaginal 207 133 239 265 258 324 MG-9
t1:93 GRE11 Greece 2010 Vaginal 207 133 239 265 258 324 MG-9
t1:94 GRE12 Greece 2010 Vaginal 264 127 239 277 258 324 MG-4
t1:95 GRE13 Greece 2010 Vaginal 230 139 239 277 260 298 MG-2
t1:96 GRE16 Greece 2010 Vaginal 207 133 239 265 258 324 MG-9
t1:97 GRE17 Greece 2010 Vaginal 230 127 239 268 258 324 MG-7
t1:98 GRE18 Greece 2010 Vaginal 264 127 239 277 258 324 MG-4
t1:99 GRE19 Greece 2010 Vaginal 215 127 225 265 279 321 MG-45
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148 (13 out of 127; 10 %), MG-4 (11 out of 127; ∼9 %) andMG-7
149 (7 out of 127; 5 %). The remaining 43 genotypes were found
150 with an incidence of below 5 % (Table 1). In total, we ana-
151 lyzed 51 vaginal samples, 30 blood samples, and 17 from
152 urine as the three most common sample types, whereas the
153 remaining 29 were from a variety of other specimens.
154 However, statistical analysis showed no significant associa-
155 tion between the microsatellite genotypes and the origin or
156 date of isolation of our isolates.
157The predominant genotype MG-9 was found in 35 clinical
158samples from different countries and in two environmental
159samples (insect larvae and malt) in South Africa. Most of the
160MG-9 isolates were found in Italian (12 out of 37; 32 %) and
161African (10 out of 37; 27 %) specimens, whereas the remain-
162ing isolates were spread over Spain, Greece, and the Middle/
163Northern European countries (Fig. 1). Interestingly, another
164closely related genotype (MG-4), was also frequently encoun-
165tered in Italy (3 out of 11; 27%) and Africa (4 out of 11; 36%;
t1:100 Table 1 (continued)
Isolate Origin Year Samples Microsatellite loci Genotype
t1:101 ERG3 RPM2 MTI GLM4 GLM5 GLM6
t1:102 SAN1B Morocco 2015 Vaginal 216 134 238 271 260 298 MG-31
t1:103 SAN2 Morocco 2015 Vaginal 235 125 230 263 256 287 MG-37
t1:104HSJ118 Portugal 2005 Blood 205 131 238 280 256 321 MG-33
t1:105 8B Portugal 2004 Urine 205 131 238 263 256 321 MG-34
t1:106 CIPO55 Portugal 2005 Feces 205 131 238 263 256 321 MG-34
t1:107 CIPO102 Portugal 2005 GI tract 235 125 230 265 256 321 MG-36
t1:108HSJ42 Portugal 2005 Blood 205 131 238 263 256 321 MG-34
t1:109 CIPO88 Portugal 2005 Vaginal 205 131 238 263 262 318 MG-35
t1:110HSJ177 Portugal 2005 Blood 205 131 238 263 256 321 MG-34
t1:111HSJ117 Portugal 2005 Blood 205 131 238 263 256 321 MG-34
t1:112 CIPO103 Portugal 2005 RF 228 125 237 265 256 321 MG-38
t1:113HSJ96 Portugal 2005 Blood 262 125 327 275 256 321 MG-42
t1:114 30C Portugal 2004 Vaginal 205 131 238 263 256 321 MG-34
t1:115H38 Portugal 2004 Vaginal 205 131 238 263 256 321 MG-34
t1:116HSJ54 Portugal 2005 Blood 205 131 238 263 256 321 MG-34
t1:117HSJ55 Portugal 2005 Blood 205 131 238 263 256 321 MG-34
t1:118 CIPO44 Portugal 2005 Feces 205 131 238 263 256 321 MG-34
t1:119 TUR1 Turkey 2014 Blood 198 125 236 272 295 292 MG-46
t1:120 TUR2 Turkey 2013 Blood 205 131 238 263 256 321 MG-34
t1:121 TUR3 Turkey 2014 Urine 228 137 237 275 258 295 MG-18
t1:122 TUR4 Turkey 2014 Urine 228 125 231 265 270 295 MG-43
t1:123 TUR5 Turkey 2013 Urine 228 125 237 265 256 321 MG-38
t1:124 TUR6 Turkey 2014 Urine 262 130 231 275 258 295 MG-19
t1:125 TUR7 Turkey 2013 Urine 205 131 238 263 256 321 MG-34
t1:126 TUR8 Turkey 2014 Urine 198 124 236 265 268 287 MG-47
t1:127 TUR9 Turkey 2014 Urine 205 131 238 263 256 321 MG-34
t1:128 TUR10 Turkey 2014 CSF 228 125 237 265 256 321 MG-38
t1:129 TUR11 Turkey 2013 Blood 228 125 237 265 255 321 MG-39
t1:130 TUR12 Turkey 2015 Urine 198 125 236 272 295 292 MG-46
t1:131 TUR13 Turkey 2014 Blood 198 125 236 272 295 292 MG-46
t1:132 TUR14 Turkey 2015 Urine 234 125 237 278 258 321 MG-41
t1:133 TUR16 Turkey 2014 Urine 243 125 237 268 256 321 MG-40
t1:134 TUR20 Turkey 2014 Blood 228 125 237 265 256 321 MG-38
BPS biopsy of the paravertebral space, BAL bronchoalveolar lavage, CVC central venous catheter, GM case of generalized mycosis, GI gastrointestinal,
RF respiratory fluid, CSF cerebrospinal fluid
a Same patient
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166 Fig. 1, Table 1). Conversely, the second most common geno-
167 type (MG-34) found in this study was exclusively recovered
168 from Portuguese and Turkish clinical samples. This clone,
169 together with the MG-38 genotype and a number of closely
170 related genetic variants, form a particular cluster of isolates
171 evolutionarily distinct from other European isolates (Fig. 1).
172 All our observed microsatellite genotypes form a large net-
173 work in the MStree analysis with no outliers (Fig. 1).
174 However, several related CCs or microsatellite classes can
175 be defined based on the central, dominant genotypes. For
176 our analysis, we defined four clonal clusters (CC1, CC2,
177 CC3, and CC4) with the following central types MG-34,
178 MG-13, MG-9, and MG-7 respectively (Fig. 1). The CC1,
179 with MG-34 as the central type, contains the genotypes MG-
180 18, MG-19, and MG-32 to MG-43; CC2, with MG-13 as the
181 central type, contains MGs 14, 17, 20, 21, and 24–28; CC3,
182 withMG-9 as the central type, includesMGs from 8 to 12, 15,
18329, 31, 46, and 47, while the remainder (MGs 1–7, 16, 22, 23,
18430, 44, and 45) fall into CC4, with MG-7 as the central type
185(Fig. 1).
186According to their geographical origin, our isolates can be
187subdivided into seven different populations (Table 3). Even
188though the populations differed in their sample sizes, the num-
189ber of haplotypes detected in each population and the numbers
190of private haplotypes specific to a given population did not
191differ very much. Portugal and Spain were the two countries
192with the lowest haplotypic richness and diversity, whereas the
193highest were in Middle/Northern Europe and Turkey
194(Table 3). However, a normalized pairwise population matrix
195of Nei’s genetic distance showed that Portugal and Turkey in
196particular were more distant Q1from the other countries.
197The populations of Africa, Middle/Northern Europe, Italy,
198Greece, and Spain did not differ significantly from one anoth-
199er (p values >0.05) whereas the Portuguese and Turkish
Fig. 1 Minimum spanning tree showing the differences based on a
categorical analysis between the genotypes. Each circle represents a
unique haplotype with the number of isolates of that genotype inside
subdivided by country of origin based on the colors. Numbers at the
connecting lines correspond to the number of identical microsatellites
between the isolates. Similarities between genotypes were visualized
using BioNumerics version 4.61 treating the data as categorical
information
t2:1 Table 2 Number of alleles and
index of diversity for each
microsatellite marker examined in
this study
t2:2 Microsatellite loci Total
t2:3 ERG3 RPM2 MTI GLM4 GLM5 GLM6
t2:4 Number of alleles 19 12 14 11 13 15 84
t2:5 Range size (bp) 181–260 121–139 227–247 261–288 259–307 280–325 –
t2:6 Diversity index 0.85 0.78 0.64 0.79 0.62 0.70 0.89
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200 populations differed significantly from all others (p values of
201 6.7e-4Q3 and smaller), but not between themselves (p
202 value=0.330).
203 Discussions and conclusions
204 In recent years, important changes in the epidemiology of
205 candidiasis have been observed worldwide, highlighting a
206 significant increase in non-C. albicans species with different
207 degrees of virulence and pathogenicity [3, 15]. Among these
208 species, C. glabrata has emerged as an important cause of
209 human disease, proving to possess an extraordinary ability to
210 infect different body sites [3–7, 19]. However, based on our
211 results, it seems that not all C. glabrata isolates are equally as
212 likely to cause human infections and some of them, especially
213 those with the MG-9 haplotype, appear to be clinically most
214 relevant and cause disease significantly more often than others
215 (Fig. 1). This remarkable capacity of some isolates to infect
216 different host tissues may be the result of their unique genetic
217 background (Table 1). This observation agrees with previous
218 studies [12, 14] and suggests that the identification of specific
219 genotypes could represent an important step for future studies
220 on the virulence of C. glabrata.
221 In this study, the combined analysis of the six microsatellite
222 markers reached a D value of 0.89 and the 127 C. glabrata
223 isolates were divided into 47 different genotypes. OurD value
224 was not consistent with that reported by Abbes et al. [11], and
225 it is below the desirable value of 0.95 for an “ideal” typing
226 system [20]. Therefore, our results suggest that the present
227 markers should be used with caution if utilized in an attempt
228 to recognize outbreaks of infections, but they can be used for
229 some population studies.
230 In this study, we were able to recognize at least four CCs.
231 Looking at the distribution of these clonal complexes over the
232 different geographical regions sampled, we observed an ex-
233 pansion of closely related genotypes (MG-9, MG-7, and MG-
2344) that were prevalent in southern countries (Italy and Spain)
235and in Africa and were probably spread by the huge flow of
236migrants that occurs between these two continents.
237Conversely, two closely related genotypes, MG-34 and MG-
23838, were restricted only to Turkey and Portugal, even if they
239showed distantly genetic relationships with the African types
240MG-37, MG-32, and MG-14. This latter, together with the
241other Nigerian MG-13, correlates more directly with the main
242type, MG-9.
243TheMG-9 type was the most frequently observed genotype
244spreading between Africa and European countries for long
245periods of time. In fact, infections caused by this genotype
246date back to more than 80 years ago (1935) as demonstrated
247by some C. glabrata strains in the CBS culture collection that
248were isolated during the two decades between 1935 and 1955
249(Table 1).
250All other clinical isolates were recovered during or after
2512004 and the MG-9 genotype was still present in recent clin-
252ical samples by demonstrating its exceptional, strong adapta-
253tion to specific geographical areas. Hence, the MG-9 seems to
254be the main European type, while its branching out to other
255main genotypes via the German MG-8 and the UK sample
256MG-10 suggests that these branches might have been crucial
257to the expansion of C. glabrata in Europe.
258Even though in part, the same set of microsatellite loci was
259used in otherC. glabrata population studies, it proves difficult
260to directly compare the results, as small size differences can be
261observed in the dominant types. These could be due to actual
262size differences or to errors in the measurements. To avoid
263such problems in the future we advocate the use of a standard
264set of reference strains, available from public sources. For this
265purpose we deposited a representative panel of strains (MGs
2667, 9, 13, and 34 in this study) to the CBS culture collection
267(www.cbs.knaw.nl) in Utrecht, the Netherlands, and the
268strains are also available from the corresponding author.
269In conclusion, the data reported here emphasize the role of
270specificC. glabrata genotypes in human infections for at least
t3:1 Table 3 Population analysis
based on the microsatellite
haplotypesQ2
t3:2 Population n A P Ne Rh He Dsh
2
t3:3 Africa 22 9 6 3,841 5,372 0775 627,636
t3:4 Greece 15 9 4 6,429 7,190 0905 822,749
t3:5 Italy 30 11 8 4,787 5,865 0818 884,636
t3:6 Middle/Northern
Europe
13 9 5 6,259 8,000 0910 361,863
t3:7 Portugal 15 6 4 2,143 4,333 0571 643,863
t3:8 Spain 16 8 5 4,000 5,873 0800 657,771
t3:9 Turkey 16 10 8 7,529 7,682 0925 860,621
t3:10 Mean± SD 18± 5.9 9 ± 1.6 5.7 ± 1.7 5.0 ± 1.9 6.3 ± 1.3 0.81 ± 0.12 694 ± 182
N sample size in each population, A number of haplotypes detected in each population, P number of private
haplotypes, Ne effective number of haplotypes, Rh haplotypic richness, He genetic diversity, Dsh
2 mean genetic
distance between individuals, SD standard deviation
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271 a few decades. We recommend further genetic studies that
272 may detect a different reality than that currently known with
273 regard to the population structure, epidemiology, and spread
274 of this fungal pathogen.
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